A recently approved AML drug, venetoclax, targets the mitochondrial protein BCL-2 for inhibition and has seen some success in survival and remission rate; however, many patients have become resistant to venetoclax treatment [52]. Here, BCL2 is linked to acute myeloid leukemia.